0001209191-21-045065.txt : 20210702 0001209191-21-045065.hdr.sgml : 20210702 20210702170248 ACCESSION NUMBER: 0001209191-21-045065 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210701 FILED AS OF DATE: 20210702 DATE AS OF CHANGE: 20210702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHERMAN JEFFREY W CENTRAL INDEX KEY: 0001230482 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 211071204 MAIL ADDRESS: STREET 1: C/O IDM PHARMA, INC. STREET 2: 9 PARKER, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: Horizon Pharma plc DATE OF NAME CHANGE: 20140919 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-07-01 0 0001492426 Horizon Therapeutics Public Ltd Co HZNP 0001230482 SHERMAN JEFFREY W C/O HORIZON THERAPEUTICS PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4 IRELAND 0 1 0 0 EVP and Chief Medical Officer Ordinary Shares 2021-03-10 5 G 0 E 66730 0.00 D 14402 D Ordinary Shares 2021-03-10 5 G 0 E 66730 0.00 A 66730 I By Spouse Ordinary Shares 2021-07-01 4 S 0 5287 95.00 D 9115 D Ordinary Shares 2021-07-01 4 S 0 54789 95.0026 D 128845 I By Trust Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on June 1, 2021 pursuant to an employee stock purchase program. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Miles W. McHugh, Attorney-in-Fact 2021-07-02